Tag Archives: Alan Carr

Albireo Pharma Inc (ALBO) Receives a Buy from Needham

Needham analyst Alan Carr maintained a Buy rating on Albireo Pharma Inc (ALBO – Research Report) today and set a price target of $50. The company’s shares opened today at $24.94. Carr observed: “Albireo provided a quarterly corporate update today

Neurocrine (NBIX) Receives a Buy from Needham

In a report released today, Alan Carr from Needham maintained a Buy rating on Neurocrine (NBIX – Research Report), with a price target of $125. The company’s shares opened today at $106.56. Carr noted: “Neurocrine reported $111.3M in 3Q18 Ingrezza

Regulus (RGLS) Receives a Hold from Needham

In a report released today, Alan Carr from Needham maintained a Hold rating on Regulus (RGLS – Research Report). The company’s shares opened today at $2, close to its 52-week low of $1.71. Carr wrote: “Regulus announced this morning another

Alnylam Pharma (ALNY) Receives a Buy from Needham

Needham analyst Alan Carr maintained a Buy rating on Alnylam Pharma (NASDAQ: ALNY) today and set a price target of $152. The company’s shares opened today at $94.10. Carr commented: “Alnylam is expected to announce results of an interim analysis

Needham Maintains Their Buy Rating on Zealand Pharma A/S (ZEAL)

Needham analyst Alan Carr maintained a Buy rating on Zealand Pharma A/S (NASDAQ: ZEAL) today and set a price target of $26. The company’s shares opened today at $15.91. Carr commented: “Zealand mgmt hosted a conference call today to discuss

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN) and Eagle Pharmaceuticals Inc (NASDAQ: EGRX)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) and Eagle Pharmaceuticals Inc (NASDAQ:EGRX). Biohaven Pharmaceutical Holding Co Ltd (BHVN) In a report released today, Alan Carr from